Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentamicin-EDTA Lock for Catheter-Related Infections
NCT04789928Phase 1Completed
- Sponsor
- Institut Pasteur
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gentamicin and ethylenediaminetetraacetic acid in catheter-related bloodstream infection (CRBSI), sponsored by Institut Pasteur. Primary endpoint: Frequency of clinical and microbial cure. Started Jan 2021; status: completed.
02
Drugs
gentamicinethylenediaminetetraacetic acid
03
Conditions
catheter-related bloodstream infection (CRBSI)
Beyond the preview
Go deeper on NCT04789928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789928.